SCHEMBL3886237

SCHEMBL3886237

CN(Cc1cccc(C(=O)O)c1)S(=O)(=O)c1cc2ccccc2s1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.49
HDAC4 P56524 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
LMNA P02545 3/20 0.43
ALDH1A1 P00352 3/20 0.43
SQLE Q14534 1/20 0.43
MAPT P10636 3/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
RXFP1 Q9HBX9 2/20 0.42
HPGD P15428 1/20 0.42
MEP1B Q16820 5/20 0.42
MEP1A Q16819 2/20 0.42
ADAM10 O14672 1/20 0.41
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
MMP13 P45452 1/20 0.41
ADAM17 P78536 1/20 0.41
TAS2R14 Q9NYV8 2/20 0.41
CA2 P00918 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3879707 0.88 RAB9A (0.53) HDAC4HDAC6LMNAALDH1A1SQLE
SCHEMBL3876863 0.87 NR1H4 (0.49) LMNAALDH1A1MAPTSMN1; SMN2MMP13
SCHEMBL3872157 0.87 PPARG (0.45) TRPM8HDAC4HDAC6LMNAALDH1A1
SCHEMBL3872649 0.83 ALDH1A1 (0.49) LMNAALDH1A1SMN1; SMN2HPGD
SCHEMBL3887293 0.83 MAPT (0.49) LMNAALDH1A1MAPTSMN1; SMN2RXFP1
SCHEMBL3872970 0.81 ROCK2 (0.45) LMNAALDH1A1MAPTSMN1; SMN2
SCHEMBL3880937 0.80 RAB9A (0.52) LMNAALDH1A1MAPTSMN1; SMN2MMP13
SCHEMBL3882723 0.80 ALDH1A1 (0.51) HDAC6LMNAALDH1A1SMN1; SMN2CA2
SCHEMBL3882913 0.79 LSS (0.48) LMNAALDH1A1MAPTSMN1; SMN2
SCHEMBL3872842 0.78 POLB (0.53) LMNAALDH1A1SMN1; SMN2RXFP1MEP1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814846-B1 11BETA-HSD1 INHIBITORS EVOTEC AG (DE) 2009-04-08 EP disclosed
US-20090069323-A1 11beta-hsdi inhibitors EVOTEC AG (DE) 2009-03-12 US disclosed
EP-1814846-A1 11BETA-HSD1 INHIBITORS Evotec AG (DE) 2007-08-08 EP disclosed
WO-2006048330-A1 11ΒΕΤΑ-HSD1 INHIBITORS EVOTEC AG (DE) 2006-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069323-A1 11beta-hsdi inhibitors HSD3B1, HSD3B2, HSD11B1 TRPM8 4838/4885HDAC4 196/4885HDAC6 811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.